Allosteric effects of cardiac troponin TNT1 mutations on actomyosin binding: a novel pathogenic mechanism for hypertrophic cardiomyopathy.
The majority of hypertrophic cardiomyopathy mutations in (cTnT) occur within the alpha-helical tropomyosin binding TNT1 domain. A highly charged region at the C-terminal end of TNT1 unwinds to create a flexible "hinge". While this region has not been structurally resolved, it likely acts as an extended linker between the two cTnT functional domains. Mutations in this region cause phenotypically diverse and often severe forms of HCM. Mechanistic insight, however, has been limited by the lack of structural information. To overcome this limitation, we evaluated the effects of cTnT 160-163 mutations using regulated in vitro motility (R-IVM) assays and transgenic mouse models. R-IVM revealed that cTnT mutations Δ160E, E163R and E163K disrupted weak electrostatic actomyosin binding. Reducing the ionic strength or decreasing Brownian motion rescued function. This is the first observation of HCM-linked mutations in cTnT disrupting weak interactions between the thin filament and myosin. To evaluate the in vivo effects of altering weak actomyosin binding we generated transgenic mice expressing Δ160E and E163R mutant cTnT and observed severe cardiac remodeling and profound myofilament disarray. The functional changes observed in vitro may contribute to the structural impairment seen in vivo by destabilizing myofilament structure and acting as a constant pathophysiologic stress.
Department of Medicine, University of Arizona, Tucson, AZ 85724, United States.
Rachel K
RK
Moore
Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724, United States.
Salwa
S
Abdullah
Department of Medicine, University of Arizona, Tucson, AZ 85724, United States; Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724, United States. Electronic address: jtardiff@email.arizona.edu.
Jil C
JC
Tardiff
D000205:Actomyosin / Q000378:metabolism*; D000595:Amino Acid Sequence; D000818:Animals; D002312:Cardiomyopathy, Hypertrophic / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D015879:Myosin Subfragments / Q000378:metabolism; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D012518:Sarcomeres / Q000235:genetics / Q000378:metabolism / Q000648:ultrastructure; D016415:Sequence Alignment; D014335:Tropomyosin / Q000378:metabolism; D020107:Troponin T / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
D015879:Myosin Subfragments; D014335:Tropomyosin; D020107:Troponin T; D000205:Actomyosin
Hypertrophic cardiomyopathy; Thin filaments; Troponin; Weak binding